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ARTICLE
In vivo clonal expansion and phenotypes of
hypocretin-specific CD4+ T cells in narcolepsy
patients and controls
Wei Jiang 1,2*, James R. Birtley 3,9,11, Shu-Chen Hung1,2,11, Weiqi Wang 4,11, Shin-Heng Chiou5,
Claudia Macaubas1,2, Birgitte Kornum6, Lu Tian7, Huang Huang 5, Lital Adler1,10, Grant Weaver 3, Liying Lu3,
Alexandra Ilstad-Minnihan1, Sriram Somasundaram 1, Sashi Ayyangar1, Mark M. Davis 2,5,8,
Lawrence J. Stern 3 & Elizabeth D. Mellins 1,2*
Individuals with narcolepsy suffer from abnormal sleep patterns due to loss of neurons that
uniquely supply hypocretin (HCRT). Previous studies found associations of narcolepsy with
the human leukocyte antigen (HLA)-DQ6 allele and T-cell receptor α (TRA) J24 gene seg-
ment and also suggested that in vitro-stimulated T cells can target HCRT. Here, we present
evidence of in vivo expansion of DQ6-HCRT tetramer+/TRAJ24+/CD4+ T cells in DQ6+
individuals with and without narcolepsy. We identify related TRAJ24+ TCRαβ clonotypes
encoded by identical α/β gene regions from two patients and two controls. TRAJ24-G allele+
clonotypes only expand in the two patients, whereas a TRAJ24-C allele+ clonotype expands
in a control. A representative tetramer+/G-allele+ TCR shows signaling reactivity to the
epitope HCRT87–97. Clonally expanded G-allele+ T cells exhibit an unconventional effector
phenotype. Our analysis of in vivo expansion of HCRT-reactive TRAJ24+ cells opens an
avenue for further investigation of the autoimmune contribution to narcolepsy development.
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W ith a prevalence of 25–50/100,000 people
1, type 1
narcolepsy (T1N) with cataplexy is a sleep disorder
that currently lacks a cure. It results from the loss of
HCRT-producing neurons in the hypothalamus, causing an
undetectable level of HCRT in the cerebrospinal fluid2. An
autoimmune etiology for T1N has been proposed for decades,
based on the discovery of an HLA class II association3. The vast
majority (~98%) of narcoleptic patients carry DQB1*06:02 (in
association with DQA1*01:02 encoding DQ6α/β heterodimers),
compared to ~25% in normal individuals4. In addition,
genome-wide association studies (GWAS) in DQ6+ individuals
revealed a risk (odds ratio~1.7) conferred by a single-nucleotide
polymorphism (SNP) haplotype, rs1154155-rs1483979. The
latter position, with G/C alleles, is located in the TRAJ24 gene
region5–7. However, how the two alternative alleles correlate
with T1N from a functional perspective remains elusive. Several
other GWAS-identified risk SNPs are located within genes that
encode proteins functioning in T cell survival and class II
antigen presentation, including the purinergic receptor
P2YR11, cathepsin H, and the co-stimulatory molecule OX40
ligand6,8,9. As CD4+ T helper (Th) orchestrate Ab and cytolytic
T lymphocyte (CTL) responses, possible contributions to T1N
from autoantibodies10–14 and CD8+ T cells15,16, complement
the genetic data in implicating a role for CD4+ T cells in the
immunopathophysiology of T1N.
A fundamental question that limits our understanding of the
proposed autoimmune origin of T1N is how to determine
the disease-specific feature of a self-reactive CD4+ T cell, given
that the peripheral T cell repertoires in both patients and
healthy individuals include diverse self-reactive clones17.
Indeed, several studies observed comparable in vitro pro-
liferative responses of CD4+ T cells isolated from T1N and
DQ6 allele-matched healthy donors18–20. Recently, one study
reported elevated responses of some patient-derived CD4+
T cells targeting HCRT, although most responding cells were
DR-restricted21, suggesting that it is challenging to use in vitro
bulk analysis to pinpoint disease-associated clones7. In order to
focus on DQ6-restricted clones, another study used DQ6-
HCRTpeptide tetramers to assess in vitro stimulated CD4+
T cells at both bulk and single-cell levels7. However, tetramer
positivity alone has been demonstrated to be insufficient for the
estimation and representation of functional reactivity of T cell
clones22.
To overcome difficulties arising from in vitro assays, we
investigate in vivo TCR clonotypic signatures and related
phenotypic characteristics at the single-cell level. We determine
the structural homology between HCRT-derived peptides that
bind DQ6 and identify CD4+ T cells that express TRAJ24 and
bind the corresponding DQ6-HCRTpeptide tetramers. Impor-
tantly, we discover features of tetramer+/TRAJ24+ cells in
some T1N patients that differ from related clones found in
some DQ6+ controls. These include: (1) the pairing of the
TRAJ24+ TCRα chain with specific β chains, both chains using
public complementarity-determining region 3 (CDR3)
sequences, (2) the ability of such TCRαβ heterodimer to
transduce functional signals in response to DQ6 presentation of
the C-terminal end of a physiologically processed HCRT neu-
rotransmitter, (3) the in vivo expansion of cells bearing these
TCRαβ clonotypes with the specific TRAJ24-G allele, and (4)
the expression by the expanded cells of transcriptional markers
indicating an unconventional in vivo T effector (Teff) pheno-
type with cytolytic potential. Our identifications of epitopes in
HCRT and in vivo expanded TRAJ24-G allele+ HCRT-reactive
TCR clonotypes advance the current understanding of HCRT-
related autoimmunity and suggest future directions for narco-
lepsy research.
Results
Rationale for approach. HCRT is the only protein known to be
unique to neurons lost in T1N2 and can be targeted by in vitro-
stimulated T cells21. Therefore, we focused on identification of
DQ6-binding HCRT peptides and used DQ6-HCRTpeptide tetra-
mers to investigate ex vivo CD4+ T cells (Fig. 1). As self-reactive
or tetramer+ clones may exist in all DQ6+ individuals7,18–20,
in vitro reactivity or tetramer binding of polyclonal T cells,
especially when analyzed in bulk7,21, is unlikely to reveal auto-
immune features of specific TCR clonotypes. We therefore
directly sequenced ex vivo DQ6-HCRTpeptide tetramer+/CD4+
single cells from DQ6+ individuals with/without T1N symptoms
using a well-established pipeline23,24. Our strategy (Fig. 1) pro-
vides direct information about in vivo clone size, an essential
feature associated with physiologic immune responses, and also
provides direct information about in vivo phenotype25–27. We
examined TCRαβ sequences to identify in vivo clonal expansions,
defined by identical variable (V), diversity (D), and joining (J)
gene regions and shared CDR3 sequences. Among these, we
focused on those that express TRAJ24, given their potential
disease-relevance. Previous work shows that HLA-peptide tetra-
mer binding does not ensure TCR functional signaling in
pathogen-specific T cells22,24,28 or tumor-infiltrating CTLs29,30.
In light of this, single-cell tetramer sorting assay likely also
overestimates the truly reactive T cell population in an auto-
immune context. Thus, our strategy to identify disease-associated
features in epitopes and in T cells does not simply rely on bulk
comparison of polyclonal tetramer+ T cells between patients and
controls; instead, the staining by tetramers served as a pre-
requisite for isolation of self-reactive candidates for single-cell
analysis. A rigorous validation for TCR function was then per-
formed in a TCR-deficient Jurkat-reporter system24 to identify
truly reactive clonotypes that can signal in response to DQ6-
HCRTpeptide.
Epitopes and binding registers in HCRT. To identify DQ6-
restricted T epitopes in prepro-HCRT (the HCRT precursor), we
used a modified version of the peptide-loading assay31 in which
HCRT peptides were tested for the ability to inhibit DQ6-binding
of EBV486–500, a known DQ6-binding epitope derived from
Epstein-Bar virus32. We evaluated overlapping 15-mer peptides,
offset by four amino acids (aa), covering the entire prepro-HCRT
sequence (Supplementary Data 1). Nine peptides showed mod-
erate to strong competitive binding (53–97.4% inhibition of the
indicator EBV peptide) to DQ6 (Fig. 2a). These were consistent
with in silico peptide-binding predictions using the
NetMHCIIpan3.2 software33 (Supplementary Fig. 1a–c). The nine
peptides span five regions (i–v) of prepro-HCRT. A strong binder
(>75% competition), HCRT1–15, was within the signal peptide
region (i) and contained a 9-aa core, LPSTKVSWA, previously
shown to bind DQ6 by X-ray structure34. Two overlapping
peptides span the C-terminus of the signal peptide and N-
terminus of the secreted HCRT1 neurotransmitter. This region
(ii) contained three possible registers as predicted by NetMH-
CIIpan3.2 using nonamers (Supplementary Fig. 1d). Using 15-
mers, the algorithm only predicted two strong cores (Supple-
mentary Fig. 1c), and our empirical-binding data further argued
that the 9-aa core SSGAAAQPL present in the strong binder,
HCRT25–39, is the dominant register (Fig. 2a). Prepro-HCRT is
processed intracellularly to two neurotransmitters, HCRT1 and
HCRT2 known to interact with the HCRT receptors, HCRTR1
and HCRTR2, with different affinities35. Interestingly, five of the
DQ6-binding peptides were from highly homologous regions (iii)
and (iv) at the C-terminal of each of the two processed neuro-
transmitters. Each region contains a NetMHCIIpan-predicted
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register (NHAAGILTL or NHAAGILTM), also implicated by
empirical binding data (Fig. 2a). The ninth peptide was a weak
binder (<75% competition) located at the prepro-HCRT C-
terminal region (v), which is removed during processing to
generate functional HCRT2. No strong binding register was
predicted for this peptide (Supplementary Fig. 1c, d).
We further investigated cores of the strong-binding peptides
using X-ray crystallography. The structure of DQ6-HCRT56–69
bound to DQ6 (Supplementary Table 1) confirmed the predicted
9-aa core register (NHAAGILTL, Fig. 2b). Comparing the DQ6-
HCRT56–69 structure with the previously determined DQ6-
HCRT1–13 structure34, we observed several conformational
changes in α-helices of the DQ6α/β dimer (Fig. 2c and
Supplementary Fig. 1e). However, the conformation of most of
the DQ6 framework that would face a TCR was unchanged. We
built on the structure of DQ6-HCRT56–69 to model HCRT25–37
and HCRT87–100 binding to DQ6 (Fig. 2d, e), and to infer
candidate TCR-facing residues. Unlike the predicted TCR contact
position P5K in HCRT1–13, neither P5G in HCRT56–69 nor P5G
in HCRT87–100 provided a side chain that could contribute to
engagement with TCR, suggesting that TCR recognition of these
complexes relied on P2/P3, or P8. HCRT25–37 contained a DQ6-
binding core with relatively short side chains at all TCR-facing
residues: P2S, P3G, P5A, and P8P. Together, these findings
predict that DQ6-restricted TCRs might bind to multiple HCRT
epitopes.
Various DQ6-HCRT tetramers stain CD4+ T cells. We next
constructed four DQ6 tetramers using peptides with strong
binding cores and tested their ability to stain CD4+ T cells iso-
lated from peripheral blood mononuclear cells (PBMCs) of T1N
donors. Tetramer-staining of T cells harboring HCRT-binding
capability only rarely showed a discrete positive population
(Fig. 3), unlike that seen with cells recognizing pathogen-derived
epitopes such as EBV486–500 (Supplementary Fig. 2). The observed
tetramer+/CD4+ T cell frequency of 0.039 ± 0.0029% was con-
sistent with a low frequency of circulating class II tetramer-
positive cells, as previously described26,36–38. Like DQ6-
EBV486–500 tetramer+ cells, which could be enriched in vitro
(Supplementary Fig. 2), frequencies of DQ6-HCRT56–69 or DQ6-
HCRT87–100 tetramer+ cells from T1N donors were significantly
increased after in vitro stimulation with the corresponding pep-
tides (Fig. 3a, b), confirming the existence of circulating HCRT
tetramer+ cells and the feasibility of using DQ6-HCRTpeptide
tetramers to isolate cells for further analysis. Cells enriched
in vitro showed specificity for the peptide stimulator, as staining
with HCRT1–13 tetramer did not appreciably increase (Fig. 3a, b).
However, we detected in vitro enrichment for DQ6-HCRT56–69
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Fig. 1 Schematic illustration of approach. a An array of overlapping peptides covering the entire candidate autoantigen HCRT is tested for HLA-DQ6
binding. b DQ6-HCRTpeptide tetramers are synthesized based on the DQ6-binding cores determined in a. c Ex vivo CD4+ T cells are isolated from PBMCs
of DQ6+ patients and controls using negative selection by magnetic-activated cell sorting (MACS); purified CD4+ T cells are co-stained with candidate
tetramers and antibodies distinguishing cell types (i.e., anti-CD4, anti-CD19). DQ6-HCRTpeptide tetramer+/CD4+ cells are sorted by single cell index
sorting (iFACS). Given the discordance between tetramer positivity and true autoreactivity, the iFACS-sorted cells likely include tetramer+ clones with
various tetramer-binding ranks, clone size, and disease-relevance: T1N-relevant (darker clones expressing public/related TCRs or unique/private TCRs) or
irrelevant (lighter clones); expansion is indicated using doublets. Clones expressing TCR risk gene alleles may also be observed in DQ6+ controls, as DQ6-
restricted selection may occur similarly in patients and controls and T1N development is thought to rely largely on antigen-driven clonal expansion. d Deep
sequencing of TCR and phenotypic transcripts in sorted single cells allows further assessment of T1N-associated gene signatures of tetramer+ clones
including both in vivo clonal expansion and expression of the TCR risk gene. e–h The DQ6-restricted TCR sequences are validated for ability to generate an
expressed α/β TCR that binds relevant tetramers and signals after stimulation with relevant peptide epitopes. The first author created this figure
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tetramer+ cells in HCRT87–100-stimulated cells from some T1N
donors (Fig. 3c). This likely reflects the high homology between
HCRT58–66 and HCRT89–97 registers and also confirms the
structural prediction that some DQ6-restricted TCRs bind mul-
tiple epitopes from HCRT (Fig. 2e).
To avoid alteration of in vivo clone size by in vitro stimulation,
we used DQ6-HCRTpeptide tetramers to directly stain and analyze
ex vivo CD4+ T cells from DQ6+ donors. These tetramers each
detected similar frequencies of circulating CD4+ T cells (includ-
ing expanded and unexpanded clones) from patients and controls
(Fig. 3d). We then sorted comparable numbers of DQ6-
HCRTpeptide tetramer+/CD4+ T cells from patients and controls
using single cell index sorting (iFACS)39 for further comparisons
of in vivo expanded clones. Prior to sequencing analysis, we used
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mean index fluorescence intensity (FI, recorded by iFACS) of
tetramer binding signal to rank tetramer+ cells. We found that
circulating DQ6-HCRTpeptide tetramer+ cells showed comparable
ranks on average between patients and controls (Fig. 3e and
Supplementary Fig. 3). These initial comparisons provided the
basis to further compare frequencies of tetramer+ clones that had
been expanded in vivo (see below), which likely reflects antigen-
driven responses.
Case/control cells with different tetramer specificities. We next
analyzed the sequencing output. iFACS screening of 3–5 million
CD4+ T cells from each donor was necessary for the isolation of
one 96-well plate of single cells (Supplementary Fig. 4). We used
blindly paired case/control PBMC samples for each experiment
(Table 1) to reduce effects of technical variations on downstream
analyses of case/control differences. In total, 5503 wells of sorted
individual cells were analyzed using the established algorithm23
(Supplementary Data 2). TCR transcripts were detected in 4605
wells (83.7% well coverage). As commonly observed with this
approach23,24,36, not every well yields called TCRαβ from raw
sequencing reads. Out of 2762 sequenced cells that had paired
TCRαβ and productive α/β CDR3 sequences, 1492 cells were
from 30 case plates and 1270 cells were from 28 control plates
(Table 1 and Supplementary Data 3), indicating the absence of
technical bias towards either cohort. However, unique to DQ6-
HCRT87–100 tetramer+/CD4+ cells, there were significantly more
called TCRαβ from cases than from controls (Supplementary
Fig. 5a). This suggests a biological difference that survives tech-
nical variations inherent in independent sort/sequence experi-
ments of case/control pairs. One possibility is that some patient
cells have generated more copies of TCR RNA due to activation at
the stage of in vivo clonal expansion, which then favors successful
single-cell sequencing.
As in vivo clonal expansion of T cells has been identified as a
feature of clones related to autoimmune diseases40, we analyzed
expanded clonotypes to further compare case/control samples
with different HCRT specificities. Overall, 52 TCRαβ clonotypes
(~1% of all sorted cells) had multiple isolates from the same
donor (Supplementary Data 3). Similar to the overall lowest
frequency of DQ6-HCRT25–37 tetramer+ cells (Fig. 3d), DQ6-
HCRT25–37 tetramers detected significantly fewer expanded
clonotypes (1 from a control C7 out of 443 cells with called
TCRαβ sequences) compared to the other tetramers (Supple-
mentary Fig. 5b). These results are consistent with HCRT25–37
peptide rarely being presented in vivo, likely due to it spanning a
border between the signal peptide and HCRT1 and harboring a
site for proteolytic cleavage. Unlike the other three DQ6-
HCRTpeptide tetramer specificities that yielded a slightly skewed
detection of more expanded clonotypes in control samples, DQ6-
HCRT87–100 tetramers identified expanded clonotypes in 5/8
patients (highly expanded clonotypes with ≥5 isolates seen in
three cases: P7, P9, and P12) vs. 2/8 controls (no highly expanded
clonotypes) (Table 1). Notably, DQ6-HCRT87–100 tetramer
detected significantly more expanded cells in patients (3.51%)
than in controls (0.8%), P= 0.0003 in a chi-squared test
(Table 2).
Expanded TCRαβ clonotypes, albeit mostly using distinct α/β
CDR3 sequences, were detected in DQ6+ controls who showed
no T1N symptoms. This could reflect T1N-irrelevant or T1N-
protective expansion or expansion triggered by non-HCRT
epitopes detectable by DQ6-HCRTpeptide tetramer due to TCR
cross-binding capacity. However, binding to DQ6-HCRTpeptide
tetramers may not reflect functional cross-reactivity given the
discordance between TCR signaling and ligand interaction22. In
line with the cross-binding hypothesis, a high percentage of
expanded clonotypes (34/52, 65.4%) in our dataset were identified
by more than one DQ6-HCRTpeptide tetramer (Table 1 and
Supplementary Data 3). The observed cross-binding capacity was
also consistent with the structural similarities in these DQ6/
peptide complexes (Fig. 2e). Interestingly, the frequency of
expanded DQ6-HCRTHCRT87–100 tetramer+ cells in subjects who
had received a recent TIV vaccination (C5, C6, C11, P5) was
significantly higher than in controls who had received no
influenza vaccination (C9, C10) or received H1N1 vaccination
~5 years prior to blood draw during the 2009 flu pandemic (C7,
C8, C12), P= 0.0476 in the Mann–Whitney U-test or P < 0.0001
in a chi-squared test. This indicates a high likelihood of detecting
cross-binding expanded clonotypes by the DQ6-HCRTHCRT87–100
tetramer in the circulating T cell repertoire after recent
stimulation. It could be more informative for a T1N analysis to
exclude TIV-vaccinated subjects when assessing case/control
differences. Indeed, the DQ6-HCRT87–100 tetramer detected 10
expanded clonotypes (24 isolates) in 4/7 cases (excluding TIV-
vaccinated P5), but none in 5/5 controls (excluding TIV-
vaccinated C5, C6, C11), P < 0.0001 in a chi-squared test assessing
the frequency of expanded cells between patients and controls
(Tables 1 and 2). The fact that none of the four patient subjects
was previously influenza-vaccinated suggests the epitope in
HCRT87–100 is relevant to the in vivo expansion of identified
clones.
TRAJ24+ clonotypes isolated by DQ6-HCRT tetramers. Most
clonotypes in our dataset (49/52 expanded or 2460/2465 unex-
panded) use unique α/β CDR3s (Supplementary Data 3).
Therefore, to investigate public features of expanded clonotypes,
we first grouped TCRαβ clonotypes based on their sharing of
identical Jα/Jβ genes. Based on the grouping, we focused on those
that expressed TRAJ24, the GWAS-identified risk gene5,6, and
that were isolated by the DQ6-HCRT87–100 tetramer. We found
that, among 57 TCR clonotypes observed more than once in our
dataset (containing 302 cells that are either expanded or public,
clone ID 1–57 in Supplementary Data 3), there were 9 (I−IX)
groups of cells that express identical TRBJ/TRAJ genes although
isolated from different subjects (Fig. 4a). These 9 groups covered
3 major types of TCRs (79 cells): Type A (15 cells) contained
non-public CDR3s using varied V genes, although J genes are the
Fig. 2 DQ6-binding cores in prepro-HCRT and their structural impacts. a Thirty overlapping peptides covering prepro-HCRT were added, individually, into a
reaction containing soluble DQ6, bio-EBV486–500 peptide, and HLA-DM (a peptide loading catalyst). DQ6-associated bio-EBV486–500 was measured at
steady state by ELISA31. %Competition= 1−%DQ6/EBV binding. Strong (>75%Competition, in colors) and weak (50–75%Competition, in gray) DQ6
binders with predicted cores (bolded) are aligned. Data are represented as mean ± SEM (standard error of the mean); n= 4. b Top view of HCRT56–69
(orange) in the peptide-binding groove of DQ6 (α/β, light green/blue surface, PDB: 6DIG). Core residues are indicated. c Alignment of DQ6-HCRT56–69
(α/β, light green/blue cartoon; peptide, orange stick) and DQ6-HCRT1–13 structures34 (α/β, dark green/blue; peptide, magenta) illustrating three regions in
DQ6 with noticeable conformation differences (detailed in Supplementary Fig. 1e). d Side view of DQ6 (β chain removed to reveal peptides) in complex
with HCRT1–13 (PDB: 1UVQ) and DQ6-HCRT56–69 (PDB: 6DIG) and models of HCRT25–37 and HCRT87–100 (sticks in the same color as in a). Arrow indicates
predicted positioning for interaction of TCRα/β CDR3s. e Zoom-in of the 9-aa core registers of peptides shown in d. Arrows indicate TCR (up) or DQ6
(down) facing resides
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13234-x ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:5247 | https://doi.org/10.1038/s41467-019-13234-x | www.nature.com/naturecommunications 5
same; Type B (12 cells) used public CDR3α encoded by
TRAV10_J18 but different CDR3β encoded by TRBV25–1 in
combination with varied Jβ genes, a sequence signature remi-
niscent of semi-invariant natural killer T (iNKT) cells41; Type C
(52 cells) used conserved/semi-public α/β CDR3s encoded by
identical V-J genes. 43 type C cells expressed highly conserved
clonotypes using TRBV29–1_TRBJ2-5/TRAV6_TRAJ24 genes
(42 expanded from C3, P3, and P9; 1 unexpanded public from
C12, all in group VIII; Supplementary Data 3). The frequencies of
these four genes used in 302 cells were significantly higher from
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Fig. 3 Tetramer+/CD4+ T cells in DQ6+ donors. a Dot-plots of CD4+ T cells stimulated in vitro with the indicated peptides followed by staining with the
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those in 2762 cells with determined α/β CDR3s or in 4605 wells
that returned TCR sequences (Fig. 4b). Therefore, the skewing of
their usage in these 302 cells, for example, a 5.65-fold increase of
TRAJ24, was unrelated to sequencing bias, but rather a reflection
of biological relevance.
We then used the GLIPH algorithm24 to group α/β CDR3s
based on their sharing of common sequence motifs (global, local,
or single as previously defined24). These motifs (Supplementary
Data 4) likely determine the antigen binding specificity of TCRs
in the corresponding groups. We found 25/204 CDR3β motifs
and 16/941 CDR3α motifs containing significantly enriched
common V genes and expanded clones (Fig. 5a). Although all
cells were sorted by tetramer specificity, it was uncommon for
expanded clonotypes from multiple subjects to use public β and α
CDR3 motifs (from the 25 β and the16 α motif groups, Fig. 5b).
Our analysis showed that, only once did clonotypes using β motif
(global-E%DRGRSET, %= varied residues) and α motif (global-
%TDSWGK) occur in three subjects (P3, P9, C12) and three
clonotypes were found to be in vivo expanded in the two patients
(Fig. 5c). In addition, all of these clones expressed TRBV29-
1_TRBJ2-5/TRAV6_TRAJ24 genes. Collectively, both analyses on
the sharing of Jα/Jβ genes and β/α CDR3 motifs suggest unique
public features of TRBV29-1_TRBJ2-5/TRAV6_TRAJ24 expres-
sing clones.
Considering the T1N genetic risk conferred by the TRAJ24
gene5,6, we next focused on all TRBV29-1_TRBJ2-5/TRAV6_-
TRAJ24 expressing clones. We found 44 such clones out of 74
TRAJ24+ cells in our dataset (Fig. 5c). All α chains used
conserved CDR3 sequences, CALxxDSWGKF(L)QF. For all
TRAJ24-bearing CDR3α sequences from our dataset, the G/C
SNP alleles were always in frame with two thymidines in the
codon TTG or TTC, encoding L/F (Supplementary Fig. 6a).
However, in vivo expansion of TCRαβ clonotypes carrying the L
variant was only observed in the two cases (P3 and P9) out of the
24 individuals tested in this study. These expanded clonotypes
(eTRAJ24L hereafter) shared similar binding features, as they
were isolated by DQ6-HCRT1–13 and DQ6-HCRT56–69/
HCRT87–100 tetramers (epitopes in HCRT56–69 and HCRT87–100
share high homology). Notably, although expanded, the clono-
type using TRBV29-1_TRBJ2-5/TRAV6_TRAJ24 genes in C3
used a less conserved CDR3β (without E%DRGRSET motif)
paired with the TRAJ24F-bearing CDR3α. In addition, the highly
expanded eTRAJ24L clonotype from patient 9 (TCR27 hereafter)
was composed of a public CDR3α observed in P7, P8, P9, P12,
and C12; and a public CDR3β observed in P8, P9, P10, C11, and
C12 (Supplementary Fig. 6). The only other isolation of this
public TCRαβ clonotype was one unexpanded cell from C12
isolated by the DQ6-HCRT25–37 tetramer (Fig. 5c). Notably, index
FI analysis showed an intermediate tetramer-binding rank for
cells expressing eTRAJ24L clonotypes (Fig. 5d), as might be
expected for a self-reactive T cell, which survived thymic selection
through low to moderate TCR affinity42 and then expanded
in vivo.
A TRAJ24-G allele+ TCR signals after binding to HCRT87–100.
To further examine whether binding to HCRT87–100 triggers the
signaling of eTRAJ24L clonotypes, we expressed TCR27 in a
TCRαβ-deficient Jurkat cell line. We also generated control
transfectants for comparison: one with TRAJ24neg TCR26 from
patient P12, which is a highly expanded and cross-binding clo-
notype that lacks public features; one with a T1N-irrelevant TCR
isolated from a CD8+ T cell; others with tetramer-identified
TRAJ24neg TCRs bearing iNKT-like signatures (Fig. 6a and
Supplementary Fig. 7a). We reconstructed TCRs using sequence-
determined α/β CDR3 nucleotides in frame with the germline
sequences of the identified gene segments (IMGT/V-QUEST43).
Flow cytometric analysis confirmed the surface expression of
these TCRs in the Jurkat transfectants (Fig. 6b and Supplemen-
tary Fig. 7d). Compared to the irrelevant control, transfectants
with TCR27, TCR26, and iNKT-like TCRs showed more TCR+/
tetramer+ cells and relatively higher staining signals of HCRT1–13
or HCRT87–100 tetramers (Fig. 6c, d and Supplementary Fig. 7c, e,
f), consistent with the initial tetramer isolation of single cells
expressing these TCRs. The moderate difference from control
(~1.5–2.5 fold in MFI) was consistent with the intermediate rank
of these TCRs, as determined by iFACS (Fig. 5d and Supple-
mentary Fig. 3).
We next tested activation of these TCR transfectants by DQ6-
restricted presentation of a HCRT epitope. TCR transfectants
were incubated with control stimuli or HCRT peptides presented
by an antigen-presenting cell (APC) line that expresses DQ6 as
the only HLA class II molecule. All transfected TCRs transmitted
a CD3/CD28-mediated signal, indicating cell surface, functional
CD3 co-expression with TCR. Specifically, DQ6-restricted
presentation of HCRT87–100 peptide to TRAJ24+ TCR27 triggered
moderate TCR-mediated signaling, out of all HCRT peptide/TCR
pairs tested using the validated Jurkat-reporter system24 (Supple-
mentary Fig. 7g, h). As a physiological amidation process
converts the C-terminal Gly98 of HCRT2 neurotransmitter to a
C-terminal amide (-NH2)35, the likelihood of HCRT87–97-NH2
being presented by DQ6 in vivo may be higher than HCRT87–100.
Consistent with this hypothesis, we found that HCRT87–97-NH2
triggered stronger signaling in TCR27 transfectants than did
HCRT87–100 (Fig. 6e and Supplementary Fig. 7i). This result
indicates that the epitope in HCRT87–97-NH2 is capable of
triggering the in vivo clonal expansion of TCR27+ cells.
Table 2 Comparison of expanded clones from controls and patients analyzed using the chi-squared test
DQ6 tetramer Controls expanded/total cells
(% cells expanded)
Patients expanded/total cells
(% cells expanded)
Chi-squared test
(P-value)
FDR correction
q-value Discovery?
(P < 0.047619)
All 134/2660 (5.04) 117/2843 (4.12) 0.1013 0.063819 No
HCRT1–13 74/1141 (6.49) 71/1143 (6.21) 0.7884 0.41391 No
HCRT25–37 2/384 (0.52) 0/576 (0) 0.0829 0.063819 No
HCRT56–69 52/384 (13.54) 20/384 (5.21) <0.0001 0.000156 Yes
HCRT87–100 6/751 (0.8) 26/740 (3.51) 0.0003 0.000315 Yes
Excluding TIV-vaccinated subjects
HCRT87–100 0/463 (0) 24/644 (3.73) <0.0001 0.000156 Yes
Statistics was corrected with the Benjamini, Krieger and Yekutieli false discovery rate (FDR)-controlling procedure, desired FDR (Q): 5%. q-value: adjusted P-value. Discovery indicates significant skewing
of expanded clonotype detection in one group versus another. Analysis excluding TIV-vaccinated subject is performed on DQ6-HCRT87–100 tetramer-sorted cells
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described24. The α/β motifs used in eTRAJ24 clonotypes (shown in red to the right of each plot) have the highest overall significance. The radius of dots
reflects the final score (see details in Supplementary Data 4). b Number of subjects with clonotypes using paired α/β motifs from the 25 β and 16 α motifs.
Motifs are color-coded as in a. #clonotype with #isolates from the indicated donor(s) is also shown on the heatmap or summarized in c. c Summary of
tetramer-identified clones expressing TRBV29-1_TRBJ2-5/TRAV6_TRAJ24 genes. The L residue of the G (SNP) allele is indicated in red. The three
eTRAJ24L clonotypes are shaded. The CDR3 sequences using E%DRGRSET and/or %TDSWGK motifs are bolded. d Tetramer binding rank of individual
eTRAJ24L+ cells. Bar graphs represent the mean ± SEM FI of all sorted CD4+/tetramer+ single cells from the indicated subject-tetramer category. Open
symbols are for only eTRAJ24L+ cells within the same subject-tetramer category, as in the corresponding bar graph. All values are normalized with
background MFI of the entire CD4+ population in the tetramer detection channel
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Phenotypic features of expanded TRAJ24-G allele+ cells. The
single-cell sequencing pipeline is particularly useful for determi-
nation of phenotypic features of expanded clones by TCR clus-
tering23. Before determination of phenotypes of eTRAJ24L+ cells,
we first analyzed the skewing of transcripts for 25 tested tran-
scriptional factors and cytokines within expanded versus unex-
panded cells. The frequencies of expanded clones positive for
TBX21 (252/283, 89% vs. 419/2295, 18.3%; by 4.8 fold), IFNγ
(107/293, 37.8% vs. 54/2295, 2.4%, by 16 fold), or PRF1 (146/283,
51.6% vs. 108/2295, 4.7%; by 11 fold) were significantly (P <
0.0001, chi-squared test) higher than that of the corresponding
transcript+ unexpanded clones (Fig. 7a, b). Notably, the in vivo
transcriptional features of expanded clones, which are associated
with ongoing or prior immune responses, did not distinguish all
tetramer+/CD4+ T cells in patients compared to controls, as this
comparison was heavily influenced by the large portion (2295
unexpanded vs. 283 expanded; 8 fold) of unexpanded cells
(Supplementary Fig. 8a and Supplementary Data 5). Consistent
with the significantly higher numbers and/or more isolates of
expanded clones from six patients (P3, P4, P7–9, and P12) and
three vaccinated controls (C3, C4, and C11) (Table 1), TBX21
(encoding T-bet) and PRF1 (encoding perforin) were found more
frequently in these nine donors (Supplementary Fig. 8b and
Supplementary Data 5). This expression pattern supports a pre-
viously proposed immune mechanism in which the in vivo
expansion of perforin-expressing CD4+ T clones with cytotoxic
potential was dependent on T-bet44.
Because the above phenotypic features are unique to expanded
clonotypes, a very similar difference was observed when the 21
eTRAJ24L+ cells found in patients were compared to 16
unexpanded TRAJ24+ cells found in controls or to 21
unexpanded TRAJ24L+ cells in all DQ6+ individuals (Fig. 7c,
d). In line with the T-bet+ effector phenotype (95.2% TBX21+)
for the 21 eTRAJ24L+ cells is the extremely low-frequency
detection of RORC (0), FOXP3 (0), and BCL6 (1/21) mRNAs.
Consistent with lack of FOXP3, expression levels of other
regulatory T (Treg) cell surface markers, CD25 and CD127, on
expanded clones, including the 21 eTRAJ24L+ cells, showed no
difference from the levels on the tetramerneg/CD4+ population
(Supplementary Fig. 9). Further, the solo TCR27 clonotype
isolated from C12 (Fig. 5c) had 0 phenotypic transcripts (Fig. 7c).
These phenotypic findings are consistent with the sequencing
results indicating in vivo expansion of eTRAJ24L+ cells.
A TRAJ24F+ clone from C3 also expanded in vivo into
effectors (100% TBX21+ vs. 12.5% in the eight unexpanded
TRAJ24F+ cells). However, these 22 cells less frequently
expressed PRF1 (40.9% vs. 81.0%, P= 0.0073, chi-squared test)
and TGF-β (18.2% vs. 71.4%, P= 0.0004), but more frequently
expressed IFNγ (77.3% vs. 9.5%, P < 0.0001) than the 21
eTRAJ24L+ cells from patients (Fig. 7c, d and Supplementary
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Data 6). This indicates that eTRAJ24L+ cells acquired a
phenotype that differs from conventional Th1 cells. The
phenotypic difference between TRAJ24+ cells in patients and
those in controls (more PRF1, P= 0.0105, and TGF-β, P=
0.0016, but less IFNγ, P= 0.0007 in patient cells) was largely
attributed to differences observed in expanded TRAJ24+ clones
(Fig. 7d and Supplementary Data 6). Collectively, these data
suggest that DQ6-restricted eTRAJ24L+ cells in T1N patients
have undergone in vivo expansion and acquired an unconven-
tional effector phenotype with cytotoxic potential, likely after
recognition of epitopes in HCRT56–69 or HCRT87–100.
Discussion
In this study, we focus on using in vivo clonal expansion together
with key genetic factors and molecular signatures to demonstrate
the existence of self-reactive CD4+ T cells and link their expan-
sion to a likely autoantigen. Tetramer staining offers an unbiased
antigen-specific approach to isolate cells of interest, which must
then be further assessed to pinpoint truly autoreactive T cells
among tetramer+ candidates. In particular, the discordance
between tetramer binding and TCR signaling, proved here in self-
antigen-binding T cells and previously in foreign-antigen-binding
T cells22,24,28–30, indicates that direct measurement of the sig-
naling capacity is critical in determination of function.
The ex vivo single-cell analysis uniquely allows determination
of in vivo clone sizes by pairing of TCRαβ and also allows linkage
of clonotype with informative phenotypic characteristics. Given
the substantial diversity in TCRαβ clonotytpes24, the low fre-
quency of tetramer+ cells, the likely involvement of polyclonal
T cells in T1N, and the potential heterogeneous pathways that lead
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to autoimmunity among different individuals, it is challenging to
directly isolate public TCRαβ clonotytpes shared by multiple
individuals. However, we identified a family of TCRαβ clonotypes
expressing TRBV29-1_TRBJ2-5/TRAV6_TRAJ24 genes from
among thousands of ex vivo accessible DQ6-HCRTpeptide tetramer
+/CD4+ cells from DQ6+ individuals with/without T1N. Notably,
this family of clonotypes observed in 4/24 donors from our study
is absent from previous in vitro studies7,21. Within our dataset,
in vivo expansions (determined by sequence and phenotype) of G-
allele+ eTRAJ24L clonotypes are only observed in T1N patients
(2/12) from the 24 donor blood samples. Related clonotypes are
absent in the other patient donors, likely due to both hetero-
geneous biology facts and technical limitations, such as the low
number of cells sequenced/donor. Nonetheless, we found clear
differences between eTRAJ24L+ cells in patients and related cells
in controls: (1) the solo isolate sharing identical α/β CDR3s with
TCR27 from a DQ6+ control has not expanded, and (2) the
expanded TRAJ24F+/CD4+ T cells isolated from another DQ6+
control possess different effector phenotype compared to
eTRAJ24L+ cells. We cannot rule out a potential role of the
TRAJ24F+ clonotype in T1N, although these cells are from a
control. Indeed, the HCRT87–97-NH2 (SGNHAAGILTM-NH2)
epitope that stimulates TCR 27 signaling is likely physiologically
available for DQ6-restricted presentation in all DQ6+ individuals.
This implies that other factors are necessary to trigger T1N
development in DQ6+ individuals who carry the risk
TRAJ24 gene.
Although antigen presentation in the central nervous system
(CNS) is not yet well-understood, a recent study has suggested
that conventional dendritic cells are essential for presenting CNS-
derived antigens and licensing Th cells to initiate neuroin-
flammation45. It is possible that the unconventional CD4+ Teff
cells that we identified receive licensing via a similar MHCII
(DQ6) presentation of NHAAGILTL(M) epitopes, and then
activate microglia to secrete neurotoxic factors or exert their own
cytotoxic potential to destroy microglia. Either process would be
detrimental to the associated neurons46. In addition, fragments of
HCRT proteins that include the epitopes may leave the CNS, and
prime T cells outside of the brain, similar to a recent murine
model in which insulin peptides released by pancreatic β-cells
initiate diabetic T cell responses at distant lymph nodes47. Our
finding of eTRAJ24L clonotypes in T1N patient PBMCs indicate
the presence and persistence of brain tissue-reactive TCR clo-
notypes in the circulation, reminiscent of recent evidence that
gluten-specific TCR clonotypes persist in blood and overlap with
clonotypes in gut biopsies from celiac patients40.
Many expanded clonotypes including eTRAJ24L bind to more
than one DQ6-HCRTpeptide tetramer. TCRs can recognize class II
bound to peptides that share certain homology but differ at some
TCR-facing residues26, likely due to the ability of a TCR to use
various modes of ligand interaction48. Our observation either
reflects a general characteristic of self-reactive T cells or implies a
unique promiscuous feature of DQ6-reactive TCRs. The former is
consistent with the finding that many memory T cells express
cross-reactive TCRs26. The latter is supported by the NetMH-
CIIpan33 prediction that alanine is preferred at all core residues of
DQ6-binding peptides that lack side chains to increase TCR
specificity. Indeed, all five regions of prepro-HCRT that generate
DQ6-binding peptides contain multiple alanine residues. The
cross-reactive potential suggests a possible molecular basis for
promotion of T1N by viral proteins during the 2009 flu pan-
demic49,50, for example by mimicking HCRT epitopes, as sug-
gested7, although functional cross-reactivity by TCRs from T1N
patients still requires further proof.
The promiscuous feature of DQ6-reactive TCRs has unexpect-
edly complicated current studies (inducing ours) that are focused
on the identification of self-antigen and truly autoreactive T cells.
It is currently unclear whether expanded multi-tetramer-binding
clonotypes other than eTRAJ24L (including the TRAJ24F+ clone
found in a control) mediate ongoing immune responses or not,
and whether these in vivo expansions are associated with
(including regulatory function) or irrelevant to T1N. Because
tetramer+ cells do not necessarily signal in response to the HLA-
peptide ligand22,24, multi-tetramer-binding also does not ensure
signaling to both epitopes, as suggested by the null function of
TCR27 transfectants in response to HCRT1–13, and the failure of
TRAJ24neg TCR clonotypes-mediated signaling in response to all
tested HCRT peptides. The physiological significance of thymic
selection for many self-binding but non-autoreactive cells may be
to maintain self-tolerance, for example by selectively sequestering
DQ6-HCRT complexes, which would otherwise trigger signaling-
competent T cells for autoimmunity. Also notable is that TRAJ24
gene can be rearranged with various Vα genes and choose from
extremely diverse β chain genes for pairing in different T cells
from different DQ6+ individuals, as observed herein and pre-
viously7,24. Therefore, polyclonal TCRs using distinct TRAJ24L-
bearing CDR3α sequences or factors other than TCRs may be
involved in T1N development in different individuals. None-
theless, our discovery of eTRAJ24L clonotypes offers a candidate
TCR for further investigation of autoimmunity in T1N.
The two homologous epitopes at the C-termini of HCRT1
(NHAAGILTL) and HCRT2 (NHAAGILTM) may make different
contributions to autoimmunity rather than redundantly boosting
the response. Indeed, HCRT1 and HCRT2 proteins differ in
stability and binding affinities to HCRTR1 and HCRTR2 recep-
tors35, with possible consequences for tolerance. Our findings
thus raise the next set of mechanistic questions, while uncovering
molecular linkage between autoimmune effectors and targets
in T1N.
Methods
Construction of recombinant HLA–DQ6–HCRT complexes. A stable Drosophila
Schneider 2 (S2) insect cell line secreting soluble DQ6 proteins was previously
constructed31. In this construct, the class II-associated invariant chain peptide,
CLIP87–101 (aa: PVSKMRMATPLLMQA), is covalently linked to the β chain of
DQ6 α/β heterodimers. The DQ6 construct includes the extracellular portion of
HLA-DQA1*01:02 followed by a 3C protease cleavage site and leucine zipper-Fos
sequence and the extracellular portion of HLA-DQAB1*06:02, preceded by the
peptide sequence and a thrombin-cleavable linker sequence
(GGGGSLVPRGSGGGG), and followed by a 3C protease cleavage site and leucine
zipper-Jun sequence. Similarly, we constructed five S2 cell lines expressing soluble
DQ6-HCRT1–13 (aa: MNLPSTKVSWAAV), DQ6-HCRT25–37 (aa: ALLSS-
GAAAQPLP), DQ6-HCRT56–69 (aa: AGNHAAGILTLGKR), DQ6-HCRT87–100
(aa: SGNHAAGILTMGRR) and DQ6-EBV486–499 (aa: RALLARSHVERTTD),
respectively. Briefly, two plasmids (encoding α and β chains of DQ6) were used for
the expression of each DQ6–peptide complex in S2 cells. The α chain-encoding
plasmid is shared by all constructs, and the β chain-encoding plasmids were
modified via polymerase chain reactions (PCR) and sub-cloning to swap the
nucleotide sequence encoding corresponding peptides that were covalently tethered
to the N-terminus of DQ6β. S2 cells were co-transfected following the user guide
for Drosophila S2 cells (Invitrogen, Thermo Fisher Scientific) with α-encoding and
β-encoding plasmids as well as a third plasmid carrying the neomycin (geneticin)-
resistance gene, at a ratio of 20:20:1. Geneticin (G418)-resistant S2 transfectants
were recovered after 2–3 weeks of culturing in Schneider Drosophila medium with
10% heat-inactivated fetal bovine serum (HI FBS), 2 mM glutamine and 1.5 mg/ml
G418 (all from Thermo Fisher Scientific). Stable cell lines were established after
another 2–3 weeks of culturing and selection under G418.
Expression and purification of soluble HLA proteins. Stable S2 cell lines
secreting soluble HLA proteins (e.g., a DQ6-HCRTpeptide complex or DM31) were
initially cultured in the complete Schneider medium and gradually adapted to S2
serum-free medium (Thermo Fisher Scientific) before the induction of protein
expression using 1 mM copper sulfate. After 1-week induction, bacteriostatic
protease inhibitors, such as 1 mM phenylmethane sulfonyl fluoride (PMSF), 1 mM
ethylenediaminetetraacetic acid (EDTA), and 0.02% sodium azide (NaN3), were
added to the S2 culture, which was then centrifuged to collect supernatants con-
taining soluble HLA proteins. The 0.22 micron membrane-filtered supernatant was
then applied onto a column for the purification of target proteins by affinity
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chromatography. A customized anti-DQ column containing SPV-L3 Ab31 was
used to purify DQ6 and a column composed of M2 (anti-FLAG tag) resins (Sigma)
was used to purify DM. Affinity-purified proteins were further concentrated and
isolated from aggregates or degraded material by size-exclusion chromatography,
using either Superdex increase 200 10/300 GL or HiLoad 16/60 Superdex 200 gel
filtration columns (GE Healthcare). Fractions were eluted with TBS buffer (e.g., 20
mM Tris–Cl, 150 mM NaCl, pH 7.4) and the ones containing monomeric forms of
each protein were pooled. Protein purity was confirmed using Coomassie and
western blotting analyses, and protein functionality was validated in the peptide-
binding assay, as described below.
Peptide competition assay. The ability of a peptide to inhibit the interaction of
DQ6 and a reference binding peptide at steady state was used to estimate the
relative DQ6-binding capacity of test peptides. We used biotinylated EBV486–500
(aa: biotin-GGGRALLARSHVERTTDE, synthesized by Genscript), a DQ6-binding
peptide (epitope underlined) derived from Epstein-Barr virus nuclear antigen32, as
our reference peptide. Non-biotinylated test peptides included 30 15-mer over-
lapping peptides derived from prepo-HCRT (Supplementary Data 1a, by Gen-
script) and the positive control peptide EBV486–500. The DQ6-CLIP87–101 construct
contains a thrombin cleavage site in between CLIP87–101 and DQ6β. To cleave the
covalent linker and enable replacement of CLIP87–101 by high-affinity DQ6 binders,
soluble DQ6-CLIP87–101 at a concentration of 3 μM was incubated with 0.002 U/μl
thrombin enzyme (Novagen, EMD Millipore) for 2 h at room temperature (RT)
prior to peptide loading experiments. To test DQ6-binding capacity, a non-
biotinylated peptide at 40 μM was mixed with 1 μM biotinylated EBV486–500 and
incubated with 25 nM thrombin-cleaved DQ6-CLIP87–101. 100 nM soluble DM was
added as a catalyst to increase the peptide exchange efficiency31. The reaction was
carried out under acidic conditions in 100 mM acetate buffer (acetic acid and
sodium acetate, pH 4.6), 150 mM NaCl, 1% (w/v) BSA, 0.5% (v/v) IGEPAL CA-630
(Sigma), 0.1% (w/v) NaN3, at 37 °C for 20 h. After incubation, the peptide exchange
reaction was stopped by the addition of two volumes of the neutralization buffer
[100 mM Tris–Cl (pH 8.3), 150 mM NaCl, 1% (w/v) BSA, 0.5% (v/v) IGEPAL CA-
630, 0.1% (w/v) NaN3], and the mixture was transferred to an SPV-L3-coated 96-
well plate and incubated at RT for 1 h. Time-resolved fluorescence representing
DQ6-associated biotinylated EBV486–500 captured by SPV-L3 in each well was then
quantified using the DELFIA Eu-N1 Streptavidin System (PerkinElmer).
DQ6-HCRT crystallization and structure determination. DQ6-HCRT56–69 pro-
teins purified from S2 culture were incubated with recombinant HRV 3C protease
(3Cpro, Novagen, EMD Millipore) at 4 °C overnight to remove the leucine zipper at
the C-termini of DQ6α/β heterodimers. 3Cpro-cleaved DQ6-HCRT56–69 was fur-
ther purified by anion exchange chromatography using HiTrap Q HP and finally
by gel filtration using HiLoad 16/60 Superdex 200 (GE Healthcare). For crystal-
lization, DQ6-HCRT56–69 was concentrated to 10 mg/ml in 20 mM Tris–Cl pH 7.5,
20 mM NaCl, 0.01% NaN3. Thin elongated plates measuring ~300 × 100 × 20 µm
were obtained after 5 days at room temperature by mixing 1 µl of protein with 1 µl
of precipitant solution containing 16% PEG 8K, 0.1 M Mg acetate, and 0.1 M
glycine pH 4.5. Crystals were flash-frozen by mixing 75% mother liquor (v/v) with
25% saturated sucrose. X-ray diffraction data were recorded at 100 K (λ= 0.9793
Å) at the LRL-CAT 31-ID beamline Advanced Photon Source (APS) in Chicago.
Images were processed using Mosflm version (7.1.1)51 and scaled with SCALA52.
Initial phases were obtained by molecular replacement with Phaser53 based on the
DQA1*01:02/DQB1*06:02 α-chain and β-chain from PDB file 1UVQ34. One strong
molecular replacement solution was found with 1 molecule per asymmetric unit
each of the α-chain and β-chain. The solution was confirmed by examination of
composite omit maps. After one round of rigid body refinement, the hypocretin
peptide was built manually and the whole model improved by cycles of manual
building and refinement using COOT54 and PHENIX REFINE55, respectively. The
overall geometry in the final structure is good, with 98.6% of residues in favored
regions, 1.4% in allowed regions of the Ramachandran plot and no outliers. Data
collection and refinement statistics are reported (Supplementary Table 1). Residues
105–112 of the β-chain are missing in the electron density, likely due to disorder,
and were not included in the structural model. Residues 56–68 of the DQ6-
HCRT56–69 peptide sequence AGNHAAGILTLGK was built into clear electron
density in the peptide-binding cleft, but no electron density was observed for
arginine 69 and the linker (GGGGSLVPRGSGGGG) tethering the peptide to the
N-terminus of the β chain. A monosaccharide of N-acetyl glucosamine was built at
asparagine residues 81 and 121 of the α chain and a disaccharide at asparagine 19
of the β chain. One molecule of Tris was modeled into the electron density. Two
amino acid side chains in the β chain were disordered (Arg 48 and Glu 59) and
were refined with two alternative conformations. Structural biology software used
in this project was curated by SGgrid56. Structure figures were generated using the
program PyMOL57.
In silico analysis using NetMHCIIPan. We used the MHC-II peptide-binding
prediction website, NetMHCIIpan 3.233, to evaluate potential DQ6-binding core
epitopes within the prepro-HCRT sequence. The resultant in silico predictions of
binding rank for HCRT-derived peptides at various lengths are reported (Sup-
plementary Data 1b–d). The peptides containing strong predicted core registers
(Supplementary Fig. 1) were analyzed in experimental binding assays. The
NetMHCIIpan 3.2 motif viewer displays binding motifs and predicts that DQ6
(DQA1*0102/DQB1*0602) prefers alanine over all other residues at each of the 9
anchor positions of a potential binding peptides, with small residues, such as serine,
glycine, and threonine also preferred at most of the positions.
DQ6-HCRT modeling and structural analysis. Models for HCRT-derived pep-
tides bound to DQ6 were developed using the DQ6-HCRT56–69 structure. HCRT-
derived peptides shown to bind to DQ6 by competition binding studies were
docked onto the DQ6-HCRT56–69 structure using the 9-aa core epitope defined by
NetMHCIIpan for alignment. Peptide side chain rotamers and if necessary DQ side
chain rotamers were adjusted using Pymol57 to accommodate the sequence
changes without steric clashes; adjustment of peptide or DQ6 main chain con-
formation was not required.
Human subjects and peripheral blood samples. All donors in this study are
HLA-DQB1*06:02+. Narcoleptic patients with cataplexy met the criteria for
International Classification of Sleep Disorders 3 (ICSD3) for T1N58. The controls
are either unrelated or influenza-vaccinated subjects. Influenza vaccines included
Pandemrix (an AS03-adjuvanted 2009 H1N1 influenza vaccine formulation, GSK)
or a seasonal trivalent-inactivated influenza vaccine (TIV, Fluzone, NDC 49281-
705-55, 2012–2013 formula, Sanofi Pasteur). PBMCs were received from the
Stanford Center for Sleep Sciences and Medicine. Written consent was obtained for
collection of all PBMC samples under a Stanford Institutional Review Board
approved protocol, following the guidelines for human subjects’ research under U.
S. Department of Health and Human Services human subjects regulations (45 CFR
Part 46).
Tetramer synthesis. Customized DQ6-peptide tetramers were all synthesized by
NIH Tetramer Core Facility at Emory University using monomers that were
secreted from a mammalian cell expression system. These recombinant DQ6-
peptide monomers including DQ6-HCRT1–13, DQ6-HCRT25–37, DQ6-HCRT56–69,
DQ6-HCRT87–100, and DQ6-EBV486–499 used identical constructs as mentioned
above in the S2 expression system. In each tetramer, peptides are covalently
tethered to the N-terminus of DQ6β in order to maintain the peptide specificity.
In vitro culturing of CD4+ T cells. To test for the presence of DQ6-HCRTpeptide
tetramer+/CD4+ T cells, a peptide-loaded antigen-presenting cell (APC) line
T2DQ6 (fixed to limit APC proliferation) was co-cultured with T cells for DQ6-
restricted antigen stimulation. T2DQ6 was constructed by stable transfection of
DQ6 (DQA1*01:02/DQB1*06:02) into T2, a class II-deficient TxB hybrid cell31.
T2DQ6 cells were maintained in IMDM, GlutaMAX supplemented media
(Thermo Fisher Scientific) with 10% HI FBS, 1% penicillin/streptomycin (P/S) and
1 mg/ml G418 (to maintain selective pressure on DQ6 transfectants). To load
antigen, T2DQ6 cells were pulsed with peptides (i.e., EBV486–500, HCRT56–69,
HCRT87–100, synthesized by Genscript) at 1 μM final concentration and incubated
for 6 h at 37 °C. After peptide loading, 10 million T2DQ6 cells were washed with
phosphate buffered saline (PBS) and then fixed by incubating with 0.025% glu-
taraldehyde in 2 ml PBS at RT for 30 s. After the addition of another 2 ml PBS, the
cells were incubated for another 10 min at RT. Fixed T2DQ6 was washed twice
with PBS and once with complete RPMI (RPMI 1640 medium supplemented with
10% HI human AB serum, 2 mM glutamine and 1% PS, Thermo Fisher Scientific)
before mixing with CD4+ T cells. Human PBMCs frozen in NUNC tubes were
thawed quickly at 37 °C and added slowly to 10 ml warm complete RPMI. PBMCs
were pelleted and resuspended in cold buffer for CD4+ T cell isolation. Cells were
isolated from the PBMCs by negative selection, using the CD4+ cell isolation kit,
according to the manufacturer’s instructions (Miltenyi Biotec). Isolated CD4+
T cells were resuspended at 1 × 106 cells/ml in warm complete RPMI and rested for
at least 1 h before mixing with fixed T2DQ6 cells that were also resuspended at 1 ×
106 cells/ml in warm complete RPMI. A mixture of 1:1 volume ratio of CD4+
T cells and T2DQ6 cells in the presence of recombinant human IL-7 at final
concentration of 2.5 ng/ml was aliquoted onto a 96-well plate and incubated at
37 °C for 6 days. On day 6 and day 9, 100 µl of the spent medium was removed
from each well and replaced with fresh complete RPMI containing recombinant
IL-7 at 2.5 ng/ml and IL-2 at 40 U/ml final concentrations. On day 12, a second
round of antigen stimulation was performed similarly, using fixed T2DQ6 cells
loaded with the corresponding peptides.
Analysis of tetramer+/CD4+ cells in the in vitro culture. Sufficient cells from
the co-culture were collected, washed with complete RPMI, and resuspended in 5
ml complete RPMI at RT prior to Ficoll gradient separation. Cells above the Ficoll
media were washed and resuspended at 10 × 106 cells/ml in complete RPMI for
blocking. After 10 min, tetramers were added to a final concentration of 30 µg/ml
and staining was performed for 30 min at 37 °C in the dark, followed by another 15
min incubation at RT with the addition of Alexa fluor 488 anti-human CD4 and
PerCP-Cy5.5 anti-human CD19 Abs (BioLegend, to separate T cells from the TxB
hybrid T2 cells). Cells were then washed twice with chilled PBS+ 10% HI FBS and
resuspend in 200 µl PBS+ 10% HI FBS for flow cytometric analysis. Live/dead dyes
such as propidium iodide (PI, Thermo Fisher Scientific) or Via Probe (7-AAD, BD
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Biosciences) were added to each sample before acquisition on a flow cytometer.
Cytometers included FACSCallibur, LSR II, and FACSAria II (BD Biosciences).
Single cell index sorting (iFACS) of tetramer+/CD4+ cells. Frozen PBMCs
were received as randomized pairs each composed of one patient sample with one
control sample for a blinded study. The Mellins laboratory performed two sets of
independent experiments using PBMCs from 12 patient/control pairs of DQ6+
donors. In Set A, cells of control (C) or patient (P) subjects 1–4 were stained with
DQ6-HCRT1–13 or DQ6-HCRT56–69 tetramer. In Set B, cells of C or P 5–12 were
stained with DQ6-HCRT1–13 or DQ6-HCRT87–100 tetramer and selected samples
(C7, 8, 11, 12, and P7–12) were stained with HCRT25–37 tetramer (Table 1). Paired
PBMC samples were thawed and used for CD4 T cell isolation, as described above.
Cell viability was maintained by minimizing the exposure of primary CD4+ T cells
to temperatures higher than 4 °C. 3–5 million CD4+ T cells were labeled with
LIVE/DEAD cell stains (Life Technologies, Thermo Fisher Scientific) in PBS on ice
for 30 min, and then washed and incubated at a density of 10 × 106 cells/ml in
complete RPMI with one of the following tetramers: DQ6-HCRT1–13, DQ6-
HCRT25–37, DQ6-HCRT56–69, DQ6-HCRT87–100 at a final concentration of 50 µg/
ml at 37 °C for 15 min. After the addition of anti-CD4 and anti-CD19 Abs, staining
was performed on ice for another 3 h. In Set A, anti-CD127 and anti-CD25 Abs
(BioLegend), in addition to anti-CD4 and anti-CD19 Abs, were used to evaluate the
subsets of tetramer+/CD4+ T cells in the FACS experiment. Cell samples were then
washed in PBS+ 1% bovine serum albumin (BSA) and applied on a FACSARIA II
cell sorter in the Stanford Shared FACS Facility for the single cell fluorescence-
activated cell sorting (FACS). Up to 96 tetramer+/CD4+ cells per sample were
individually sorted into a 96-well PCR plate (Eppendorf) with each well containing
10 µl of 1x OneStep RT-PCR buffer (QIAGEN). The index feature associated with
the single cell FACS (iFACS) allowed recording of fluorescence intensity (FI)
parameters of each sorted cell.
Index analysis. Data including index FI values at each channel for sorted single
cells were exported from the FACSDIVA software. To determine the tetramer-
binding rank of sorted clones within a specific subject-tetramer category, index FI
at the tetramer channel normalized by forward scatter (FSC) intensity of each
single tetramer+/CD4+ cell was compared with MFI of the tetramerneg/CD4+ cell
population that was normalized by mean FSC intensity.
Sequencing of TCR and phenotypic transcripts in single cells. Single cell
mRNA sequencing was performed after three rounds of nested PCR amplification
of TCR and phenotypic transcripts using a well-established pipeline23 with some
optimization. Briefly, OneStep RT-PCR (following QIAGEN manual) using single
cells as the template in the same 96-well PCR plate into which tetramer+/CD4+
cells were sorted was initiated on the same day when iFACS was accomplished. The
annealing temperature was set to 58 °C (used for all three rounds of PCR reac-
tions). This first round of 15 µl multiplex PCR amplified 240–300 base pairs (bps)
mRNA sequences of target TCR and phenotypic transcripts by a set of primers
recognizing 38 TCRα genes, 36 TCRβ genes, and 25 selected phenotyping marker
genes. TCR amplicons cover the V(D)J regions including CDR3 sequences. Two
slightly different pairs of specific primers were applied to amplify IFN-γ transcripts
in Set A versus Set B donor samples. TCR and phenotypic amplicons from the
same cell were then further amplified in separate 96-well PCR plates in a second
round of multiplex PCR (15 µl) using 1 µl of the RT-PCR products as the template
and HotStarTaq enzyme (QIAGEN) as the DNA polymerase. The second round
PCR amplicons (200–250 bps) in selected wells were validated by gel electro-
phoresis. In the third round of amplification, 1 µl aliquot of the second PCR
products (TCR or phenotyping, separately) was used as a template in 15 µl PCR
reaction, which incorporates Illumina paired-end (PE) sequences and a unique pair
of barcodes with amplicons in each well. The third round PCR amplicons with a
length of 350–380 bps from each well were pooled at equal proportion by volume
and purified from 2% agarose gel using Qiaquick gel extraction kit (QIAGEN). The
incorporated PE sequences enabled deep sequencing on the Illumina Miseq plat-
form (Human Immune Monitoring Center at Stanford University), whereas bar-
codes allowed deconvolution of deep sequencing data.
Sequencing data analysis. The VDJFasta algorithm23 was used to de-multiplex
raw sequencing data and assign each sequence read to a particular well in each PCR
plate according to unique plate-row–column barcodes. The average read number
per well was 6091 ± 4556. Reads with at least 95% sequence homology were
assumed to derive from a consensus sequence of the same TCR. A consensus TCRβ
sequence with over 80% reads in a well (BetaConfi >80%) was assigned to the cell.
The top one consensus TCRα sequence with over 30% reads in a well (AlphaConfi
>30%) was assigned to the cell as the dominant TCRα; whereas a second consensus
TCRα sequence with over 10% reads in the same well (altalAphaConfi >10%), if
any, was assigned to the cell as the alternative TCRα. For phenotyping markers of
the cell, the total reads containing at least 95% sequence homology to a tran-
scription factor or cytokine gene were scored. Both Illumina MiSeq deep sequen-
cing and data analysis were performed at the Human Immune Monitoring Center
at Stanford University.
GLIPH analysis. The GLIPH algorithm (https://github.com/immunoengineer/
gliph) was used to cluster TCRs with a high probability of sharing antigen-binding
specificity due to the similarity among their CDR3 sequences24. Based on the extent
of sequence similarity, three types of conserved motifs were classified: global, local,
or single motifs, respectively (Supplementary Data 4a, c). Members in a motif
group with significant enrichment of common V genes and clonal expansion were
summarized (Supplementary Data 4b, d) to reveal TCR clonotypes isolated from
more than one DQ6+ donor or in more than one tetramer categories but from the
same donor.
Construction of Jurkat cell lines expressing candidate TCRs. To encode the
entire α/β chains of a candidate TCR, the nucleotide sequences for CDR3α and
CDR3β (Supplementary Data 3) were incorporated in frame with the corre-
sponding V(D)J genes (IMGT/V-QUEST43). TCRα/β genes were then synthesized
and cloned into a plasmid pEF1a-TCRA_2A_TCRB_IRES-AcGFP1 (by GenScript).
Each reconstructed plasmid uses a mammalian promoter, EF1a to direct co-
expression of α and β chains of one candidate TCR. TCRA and TCRB are separated
by the 2A self-cleaving peptide sequence. For selection purposes, the plasmid also
encodes the green fluorescence protein (GFP) and neomycin resistance gene, with
expression driven by separate promoters. TCR-encoding plasmids were then
transfected into the TCRα/β-deficient Jurkat cell line (J76-NFATRE-luc)24 by
nucleofection following the Amaxa Optimized protocol (Lonza). Transfectants
were selected by G418 at a concentration of 1 mg/ml and recovered after 3–4 weeks
of culturing in the RPMI medium supplemented with 10% HI FBS, 2 mM gluta-
mine, and 1% PS. To avoid the heterogeneity in TCR expression observed in a
polyclonal cell line, TCRαβ+/GFP+/CD3+ cell transfectants were individually
sorted by single cell FACS, to expand clonal cell lines originating from single cell
transfactants. These clonal lines were then co-stained with PE anti-TCRα/β Abs
(BD Biosciences) and APC DQ6-HCRT tetramers to confirm the expression of
TCRs and validate their binding to tetramers using flow cytometric analysis.
T cell activation assay using a luciferase reporter. The TCR transfectants of
J76-NFATRE-luc cells expresses the NFAT-RE (response element)-luciferase
reporter gene allowing the conversion of T cell activation signaling to luciferase
activity24. 1 × 105 K562-DQ6 cells (an artificial APC line expressing the only HLA
allele: DQA1*01:02/DQB1*06:02)24 and 1 × 105 single clonal expanded TCR
transfectants of J76-NFATRE-luc cells were mixed in 100 µl RPMI medium sup-
plemented with 10% HI FBS, 2 mM glutamine, and 1% PS. The co-culture was
incubated with various stimuli at 37 °C for 1 day before quantification of the
luciferase activity. Stimuli included 10–50 mM of one HCRT peptide (i.e.,
HCRT1–13, HCRT25–37, HCRT87–100, and HCRT87–97-NH2, synthesized by Gen-
script), or 1 µg/ml anti-CD3+ 1 µg/ml anti-CD28 Abs (BioLegend) as the positive
control, or an equal volume of PBS as the negative control. After incubation, 50 µl
of co-culture was mixed with 50 µl of luciferase substrate provided in the Nano-Glo
Luciferase Assay System (Promega). The mixture was then transferred to a flat-
bottom white 96-well plate (Costar) for a measurement of chemiluminescence
using a plate reader.
Phenotypic analysis. The number of sequencing reads of a phenotyping marker in
a well is dependent on the number of amplicons resulting from three rounds of
nested PCR reactions. This number does not necessarily reflect the transcriptional
level of the marker per cell, as PCR may bias for transcripts whose amplification
occurs relatively efficient at the conditions described above. To eliminate any PCR
bias in this semi-quantitative sequencing approach, we assigned 1 or 0 to indicate
the presence or absence of reads of a phenotypic transcript in a well without
weighing its actual reads. Comparison between patient and control samples was
then performed for the overall dataset or TCR clones clustered according to dif-
ferent schemes (Supplementary Data 5b). Numbers of cells from different donors
with various tetramer-binding specificities that express each phenotypic transcript
were also compared (Supplementary Data 5c).
Statistical analysis. A two-tailed t-test was used to compare a single variable
between two groups of samples. Welch’s t-test (unequal variance t-test) was used
when the two groups of samples had unequal variances or unequal sample sizes.
The paired samples t-test was used when there were correlated pairs of samples in
the two groups or experimental pairs show strong correlation on a scatter plot.
Mann–Whitney U-test was used to compare two groups of non-normally dis-
tributed samples. In the luciferase reporter assay, the t-test was applied between the
tested TCR and the control TCR. P < 0.05 was considered as statistical significance.
The single cell pipeline and the corresponding analysis tool including GLIPH have
high sensitivity with very low false-positive rate23,24. Chi-squared test was used to
determine the statistical significance of skewing of expanded clonotype detection
between two groups. Chi-squared test was also used to determine the statistical
significance of skewing of phenotypic parameters within a TCR cluster versus
another. Each stack of P values for a set of chi-squared test was further adjusted
using the Benjamini, Krieger, and Yekutieli two-stage linear step-up procedure with
the desired false discovery rate (FDR) Q= 5%. The null hypothesis that there is no
skewing of expanded clonotype detection or there is no skewing of phenotypic
parameters between two groups was rejected, only if the P value is less than the
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adjusted cut-of value (this is shown in the table of each FDR-controlling proce-
dure). All statistics were performed with GraphPad Prism, using the built-in
analysis tool.
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.
Data availability
X-ray structural data for DQ6-HCRT56–69 crystallization has been deposited to
worldwide protein data bank (https://www.rcsb.org), PDBID: 6GIG; and the structure
has been validated. Raw single-cell sequencing data has been deposited to NCBI GEO
database (GSE135852). Processed sequencing data are provided in Supplementary
Data 2. The source data underlying the figures of this manuscript are provided as a
Source Data file. All other relevant data are available from the authors.
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